NCT02822586 is a Phase 1 clinical trial of TSEB Therapy in Mycosis Fungoides, sponsored by Virginia Commonwealth University.

Who is sponsoring NCT02822586?

NCT02822586 is sponsored by Virginia Commonwealth University.

What drugs are being tested in NCT02822586?

Interventions in NCT02822586: TSEB Therapy, Brentuximab vedotin.

What condition does NCT02822586 study?

NCT02822586 studies Mycosis Fungoides, Sézary Syndrome.

Is NCT02822586 still recruiting?

NCT02822586 is currently completed. Last updated 30 August 2019.

Last reviewed 2019-08-30 · How we verify

NCT02822586

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

Completed Phase 1 Last updated 30 August 2019

What this trial tests

Phase 1 trial testing TSEB Therapy in Mycosis Fungoides in 5 participants. Completed in 29 April 2019.

Timeline

19 December 2016

Primary endpoint
29 April 2019

29 April 2019

Quick facts

Lead sponsor	Virginia Commonwealth University
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	19 December 2016
Primary completion	29 April 2019
Estimated completion	29 April 2019
Sites	1 location across United States

Drugs / interventions tested

TSEB Therapy
Brentuximab vedotin — full drug profile →

Conditions studied

Mycosis Fungoides — all drugs for Mycosis Fungoides →
Sézary Syndrome — all drugs for Sézary Syndrome →

Sponsor

Virginia Commonwealth University

Who can join

18 and older, any sex, with Mycosis Fungoides or Sézary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the cutaneous toxicity and treatment response associated with administering concurrent TSEB and brentuximab vedotin in patients with mycosis fungoides or Sézary Syndrome.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeted Radiotherapy in Primary Cutaneous Lymphomas: Precision, Efficacy, and Evolving Strategies.
Sobolewski P, Koper M, Ciechanowicz P, Walecka I. · · 2025 · cited 1× · PMID 40940819 · DOI 10.3390/cancers17172722
[Radiotherapy for cutaneous lymphomas].
Rolf D, Eich HT. · · 2022 · PMID 36018330 · DOI 10.1007/s00105-022-05046-w

Verify or expand the search:

Other recruiting trials for Mycosis Fungoides

Currently open trials in the same condition.

NCT07055477 — A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T- · Phase 1 · recruiting
NCT06716658 — JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas · Phase 2 · recruiting
NCT06207812 — Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis · recruiting
NCT05944562 — Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome · Phase 1 · active not recruiting
NCT06508463 — Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma · Phase 1 · recruiting

Other Virginia Commonwealth University trials

Trials by the same sponsor.

NCT05936931 — Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening · NA · not yet recruiting
NCT07365839 — Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma · Phase 1 · not yet recruiting
NCT07178158 — Enhancing Addiction Treatment Through Psychoeducation · NA · not yet recruiting
NCT07531316 — Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers · Phase 1 · not yet recruiting
NCT07426913 — Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02822586 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Virginia Commonwealth University
Last refreshed: 30 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02822586.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing